PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Developing ultra-efficient combustion cycles by replacing a conventional engine's mechanical drivetrain with cleaner and compact electrical components. Libertine have created Free Piston Engines that can operate by using either fossil fuels, or renewable energy.
Their products have opportunities to provide benefits in numerous industries and the company has already had discussions with two large automotive firms and OEMs that are interested in utilising the technology. Libertine owns 28 patents and has distributed a license for its product, which is currently generating annual revenue growth of around 90%. Revenues in 2017 totalled £300k.
days to go:
Expired
investment:
£710,970
Viritech is a clean technology engineering company that is using F1-derived engineering to develop hydrogen powertrain solutions and related technologies for the automotive, aerospace, marine and distributed power industries. Viritech asserts that the Hydrogen Council forecasts that hydrogen will meet 18% of global energy demand by 2050. It aims to capture this demand through its technologies. Viritech argues that its location in MIRA Technology Park allows it access to R&D facilities used by many of the world's major automotive manufacturers, allowing it to scale its resources to meet the demands of every type of project. Viritech will use the investment to produce test hydrogen tanks, build the Apricale hypercar, complete designs for a Heavy Goods Vehicle (HGV), Sport Utility Vehicle (SUV) and a power generator, plan a larger raise and listing on AQuis Stock Exchange (AQSE) in 2022, and eventually commercialise its technology with its partner.
days to go:
Expired
investment:
£726,807
Wireless Fitness allows fitness instructors to stream their music and voice from their phone to the phones of their class participants who listen in using their own headphones. This allows users to participate in their favourite classes without disturbing other park users or nearby local residents.
days to go:
Expired
investment:
£10,041
FreeHand is a robotic surgical camera controller that aims to make surgeries precise and safer. The company cites data arguing that over 15 million keyhole surgeries are performed annually in which an additional clinician is mostly required to manually hold the camera the surgeon uses to see the operating field. The company asserts that this is not the most optimal way. FreeHand's robotic camera controller aims to solve this issue by providing steady images and precise control, saving time, and improving outcomes. The company has regulatory clearance for sale in the EU, US, and Japan. FreeHand points out that surgical robotics is one of the fastest-growing segments in Medical Technology, projected to reach $91.5 billion by 2025. It aims to become a contender in this segment. FreeHand claims that surgeons have successfully used its robotic controller in more than 15,000 procedures. The company will use the investment to expand the distributor base in Europe, Asia and Latin America, targeting over 12 million procedures annually.
days to go:
Expired
investment:
£1,003,350
Glovebox Direct is an online automotive parts, accessories and merchandise marketplace selling original equipment direct from the car and bike brands.
days to go:
Expired
investment:
£181,670
Improving the railway construction industry by collecting data to reduce inefficiencies and overspending. Rail Diary is a B2B SaaS product that is designed to analyse information on infrastructure projects to improve particular elements that plague the industry. These include the delivery, commercialisation and the health and safety of projects.
Rail Diary allows developers to monitor ongoing costs, forecast for the future and reduce the number of claims made. Rail Diary will generate revenue via a monthly subscription model ranging from £45 to £150, plus project fees.
days to go:
Expired
investment:
£50,544
Gendius is a company that aims to bring pharmaceuticals and health economics, through clinical research and evidence, to the mobile health market. Their latest innovation, Intellin, is an intelligent remote management diabetes platform, with over 140,000 downloads so far. The COVID-19 crisis has highlighted the need for remote home monitoring of patients, and the company feels that its product is a suitable contender in this domain. Intellin has a reliable connection to over 150 medical devices and apps, and also consists of a two-way communication setup with a healthcare professional via a secure dashboard. Gendius is registered as an approved vendor with AstraZeneca in Saudi Arabia and looks to establish deeper relations with the National Health Service (UK) to create a demand for its product. The company will use the investment to scale its business globally, drive commercialisation, offer an opportunity to its stakeholders, and target venture capital.
days to go:
Expired
investment:
£386,829
